BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Reports on Q1 2023 Financial Results

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair metabolism and skin therapies, has release a report on its first-quarter revenues for the period ended March 31, 2023. The company reported revenues for the quarter totaled $1,121,676, compared to $721,629 in Q1 2022. Operating expenses for the quarter came in at $1,496,537, compared to $2,978,933 for the same period in 2022, and net losses totaled $1,308,174 for the three months, compared to $2,919,775 for the same period in 2022. “I am thrilled with our team’s progress this quarter, demonstrating substantial revenue growth and a significant reduction in operating expenses,” said Jupiter Wellness CEO Brian John in the press release. “We recognize the presence of net losses, but they continue to decrease as we push toward being cash flow positive.”

To view the full press release, visit https://ibn.fm/DN0uf

About Jupiter Wellness Inc.

Jupiter Wellness is a diversified company that supports health and wellness by researching and developing over-the-counter (“OTC”) products and intellectual property. The company’s product pipeline addresses a range of conditions, including hair loss, psoriasis and vitiligo. Revenue is generated through the sales of OTC and consumer products, contract research agreements and licensing royalties. For additional information about this company, please visit www.JupiterWellnessInc.com.

NOTE TO INVESTORS: The latest news and updates relating to JUPW are available in the company’s newsroom at https://ibn.fm/JUPW

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork